1Department of Internal Medicine and Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida; 2Division of Gastroenterology, Department of Medicine, Changi General Hospital, Singapore; and 3Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, Canada
Reprint requests and correspondence: Nicholas J. Talley, M.D., Ph.D., Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224.
CONFLICT OF INTEREST
Guarantor of the article: Nicholas J. Talley, M.D., Ph.D.
Specific author contributions: First draft by NJT; all authors reviewed and edited the drafts and approved the final version.
Financial support: None for this review. The consensus conference was supported by the Journal of Gastroenterology and Hepatology, and by the Asian Pacific Association of Gastroenterology.
Potential competing interests:
Nicholas Talley: Consultant—Astra Zeneca, Cerebrio, Giaconda Ltd., Johnson & Johnson Pharmaceutical R&D, Pfizer, Procter & Gamble, Theravance, Inc., Lexicon Genetics, Inc., Astellas Pharma US, Inc., Pharma Frontiers, Ltd., Callisto Pharmaceuticals.
Research support: Takeda, Novartis, GlaxoSmithKline, Dynagen, Tioga.
Paul Moayyedi: Advisory Boards/Speaker Bureaus: Nycomed, Astra Zeneca, JanssenOrtho and Esai.
